LYCOS RETRIEVER 
Advair Diskus: Asthma
built 608 days ago
Advair Diskus® is the first and only asthma medication approved by the FDA that effectively controls constriction and inflammation at the same time. Marketed by GlaxoSmithKline in 2001, Advair Diskus® is an oral inhaler that contains both an inhaled anti-inflammatory steroid (fluticasone propionate) and an inhaled long-acting bronchodilator (salmeterol) in one easy-to-use device. Together, these two ingredients provide better control of asthma than either does individually.
Source:
Advair Diskus is a combination asthma medication containing fluticasone and salmeterol given in a dry powder inhaler to help with maintenance and prevention of asthma. This profile provides the facts you need to know about Advair.
Source:
Advair Diskus is used to control asthma and chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis. It is an oral inhaler that contains two types of medication. One is fluticasone propionate, a steroid that reduces inflammation in the lungs. The other, salmeterol, is a long-acting bronchodilator that opens up the airways. Together, the two ingredients provide better symptom control than either does individually.
Source:
The Advair Diskus inhaler contains a combination of fluticasone and salmeterol and is used to treat asthma. Fluticasone and salmeterol shrink the swelling in the airways and relax and open air passages in the lungs. Advair was approved in 2000, by the FDA and is made by GlaxoSmithKline.
Source:
Advair Diskus is used as a maintenance treatment for children and adults with asthma. It is ... used for adults with Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis. If your child is having frequent asthma symptoms, asthma attacks, and/or is frequently using his asthma control or rescue medicines, like Albuterol or Xopenex, then he may need a medicine like Advair.
Source:
Advair Diskus is used for the long-term maintenance treatment of asthma. It is used for the prevention of asthma attacks for patients who are not adequately controlled on other asthma-controller medications, or whose disease severity clearly warrants treatment with two maintenance therapies.
Source:
MORE ABOUT
Asthma